Bradley & Co. Private Wealth Management LLC Buys Shares of 179,364 Standard BioTools Inc. (NASDAQ:LAB)

Bradley & Co. Private Wealth Management LLC purchased a new position in Standard BioTools Inc. (NASDAQ:LAB) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 179,364 shares of the company’s stock, valued at approximately $314,000.

Other large investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in Standard BioTools by 188.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after buying an additional 1,597,728 shares during the last quarter. State Street Corp boosted its holdings in Standard BioTools by 26.7% during the third quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after acquiring an additional 1,157,984 shares during the period. Barclays PLC grew its position in shares of Standard BioTools by 13.2% in the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after purchasing an additional 377,195 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Standard BioTools by 2.3% in the third quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock worth $13,415,000 after purchasing an additional 154,848 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Standard BioTools by 7.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after purchasing an additional 9,995 shares during the last quarter. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Trading Down 4.9 %

Shares of LAB stock opened at $1.27 on Wednesday. The firm has a market capitalization of $470.91 million, a P/E ratio of -1.78 and a beta of 1.57. Standard BioTools Inc. has a 1 year low of $1.17 and a 1 year high of $3.04. The firm’s fifty day simple moving average is $1.65 and its 200 day simple moving average is $1.81.

Analyst Upgrades and Downgrades

Separately, TD Cowen lowered their target price on Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.